<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169544</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-488</org_study_id>
    <nct_id>NCT02169544</nct_id>
  </id_info>
  <brief_title>Post-marketing Study Assessing the Long-Term Safety of Abatacept</brief_title>
  <official_title>Post-marketing Study Assessing the Long-Term Safety of Abatacept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the risk of infections and malignancies among
      Rheumatoid Arthritis (RA) patients treated with Abatacept compared to other RA treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2014</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Actual">February 28, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of Lung Cancer</measure>
    <time_frame>Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of lymphoma</measure>
    <time_frame>Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of breast cancer</measure>
    <time_frame>Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of non-melanoma skin cancer</measure>
    <time_frame>Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of all malignancies</measure>
    <time_frame>Cancer: From 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of hospitalized infections</measure>
    <time_frame>Infection: From the index date until the first of the following: end of treatment +90 days, event of interest, death or end of study (approximately 1 year)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of pneumonia</measure>
    <time_frame>Infection: From the index date until the first of the following: end of treatment +90 days, event of interest, death or end of study (approximately 1 year)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of opportunistic infections</measure>
    <time_frame>Infection: From the index date until the first of the following: end of treatment +90 days, event of interest, death or end of study (approximately 1 year)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of tuberculosis</measure>
    <time_frame>Infection: From the index date until the first of the following: end of treatment +90 days, event of interest, death or end of study (approximately 1 year)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept or a comparison anti-rheumatic drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of lupus</measure>
    <time_frame>Outcomes will be assessed from 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of multiple sclerosis</measure>
    <time_frame>Outcomes will be assessed from 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of psoriasis</measure>
    <time_frame>Outcomes will be assessed from 180 days after the index date until the first of the following: event of interest, death, or end of study (approximately 2 years)</time_frame>
    <description>The index date is defined as the date that the patient initiates Abatacept</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100000</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RA patients who are prescribed Abatacept</arm_group_label>
    <description>Abatacept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who are prescribed other RA treatments</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <arm_group_label>RA patients who are prescribed Abatacept</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be selected from 4 US claims databases
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Patient has at least two claims for RA (714.xx) in the 180 days prior to and including
             the index date (baseline period)

          -  Patient is aged 18 years or older on the index date

          -  Patient was enrolled in the database for at least 180 days before the index date

          -  Patient is newly prescribed Abatacept or another RA treatment and has at least two
             claims for the treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

